We are commercializing a treatment for a severe form of corneal blindness called limbal stem cell deficiency. This rare disease causes a significant societal burden because it occurs especially in young and working age people. The treatment is based on IP-protected technology for differentiating highly potent limbal stem cells from human pluripotent stem cells, providing an unlimited source of therapeutic cells. Our technology is currently in the preclinical phase.
November 29th & 30th, 2022
December 7th & 8th, 2022